Lead Product(s): Viaskin peanut
Therapeutic Area: Immunology
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
These studies have been instrumental in highlighting CRV431's therapeutic strengths and have helped guideHepion Pharmaceutical'scurrent planning of NASH clinical trials.